Chronic migraine prevention from the perspective of a family doctor: a literature review
DOI:
https://doi.org/10.12775/JEHS.2024.59.013Keywords
migraine, headache, preventive therapyAbstract
Chronic migraine is a disease that significantly reduces the quality of life of patients. It affects millions of people around the world, and is common particularly among young women. Family physicians often encounter the problem of migraine headaches in their daily practice. The diagnostic problem results from absence of tests or imaging studies that can clearly indicate the cause of the headache. In order to establish a diagnosis and exclude secondary sources of pain, doctors focus on a detailed medical history and analysis of symptoms presented over time. Preventive treatment of migraine requires appropriate drug selection after weighing the benefits and risks for each patient. This review paper presents and briefly discusses selected pharmacological and non-pharmacological methods used in migraine prevention. They were selected by searching the PubMed Internet database. The presented non-pharmacological methods include the use of nutraceutics, acupuncture and behavioral therapy. The discussed pharmacological methods include treatment with beta-blockers, topimarate, flunarizine or one of the latest methods - the use of monoclonal antibodies against CGRP. In addition, the use of botulinum toxin type A in the treatment of chronic migraine has also been demonstrated. It should be remembered that the type of therapy chosen should be individualized: according to the patient's preferences, treatment effectiveness, possible side effects or accompanying diseases. Proper management of chronic migraine prophylaxis can significantly improve the quality of life of patients and reduce the frequency of headache attacks.
References
Vincent M, Viktrup L, Nicholson RA, Ossipov MH, Vargas BB. The not so hidden impact of intraictal burden in migraine: A narrative review. Front Neurol. 2022 Nov 3;13:1032103. doi: 10.3389/fneur.2022.1032103. PMID: 36408525; PMCID: PMC9669578.
Headache Classification Committee of the International Headache Society (IHS). The Inter-national Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629-808. doi: 10.1177/0333102413485658. PMID: 23771276.
Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z; Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain.
Dec 2;21(1):137. doi: 10.1186/s10194-020-01208-0. PMID: 33267788; PMCID: PMC7708887.
Burch R. Migraine and Tension-Type Headache: Diagnosis and Treatment. Med Clin North Am. 2019 Mar;103(2):215-233. doi: 10.1016/j.mcna.2018.10.003. Epub 2018 Dec 3. PMID: 30704678.
Holle D, Obermann M. The role of neuroimaging in the diagnosis of headache disor-ders. Ther Adv Neurol Disord. 2013 Nov;6(6):369-74. doi:
1177/1756285613489765. PMID: 24228072; PMCID: PMC3825114.
Puledda F, Shields K. Non-Pharmacological Approaches for Migraine. Neurothera-peutics. 2018 Apr;15(2):336-345. doi: 10.1007/s13311-018-0623-6. PMID: 29616493; PMCID: PMC5935652.
Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ.
Apr 20;182(7):E269-76. doi: 10.1503/cmaj.081657. Epub 2010 Feb 16. PMID:
; PMCID: PMC2855933.
VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Rol-dan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z .Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. CAVITY. 2021 Jun 15;325(23):2357-2369. doi: 10.1001/jama.2021.7939. PMID: 34128998; PMCID: PMC8207243.
Robblee J, Starling AJ. SEEDS for success: Lifestyle management in migraine. Cleve-land Clinic Journal of Medicine. 2019 Nov;86(11):741-749. DOI: 10.3949/ ccjm.86a.19009. PMID: 31710587.
Martin VT, Vij B. Diet and Headache: Part 1. Headache. 2016 Oct;56(9):1543-1552. doi:
1111/head.12953. PMID: 27699780.
Martin VT, Vij B. Diet and Headache: Part 2. Headache. 2016 Oct;56(9):1553-1562. doi: 10.1111/head.12952. PMID: 27699772.
Cairns BE. Influence of pro-algesic foods on chronic pain conditions. Expert Rev Neurother. 2016;16(4):415-23. doi: 10.1586/14737175.2016.1157471. Epub 2016 Mar
PMID: 26900907.
Gross EC, Klement RJ, Schoenen J, D'Agostino DP, Fischer D. Potential Protective Mechanisms of Ketone Bodies in Migraine Prevention.Nutrients. 2019; 11(4):811. https://doi.org/10.3390/nu11040811
Gazerani P. Migraine and Diet. Nutrients. 2020 Jun 3;12(6):1658. doi:10.3390/nu12061658. PMID: 32503158; PMCID: PMC7352457.
Wells RE, Bertisch SM, Buettner C, Phillips RS, McCarthy EP. Complementary and alternative medicine use among adults with migraines/severe headaches. Headache. 2011 Jul-Aug;51(7):1087-97. doi: 10.1111/j.1526-4610.2011.01917.x. Epub 2011 Jun 7.PMID: 21649654; PMCID: PMC3627391.
Puledda F, Shields K. Non-Pharmacological Approaches for Migraine. Neurothera-peutics. 2018 Apr;15(2):336-345. doi: 10.1007/s13311-018-0623-6. PMID: 29616493; PMCID: PMC5935652.
Suwannasom N, Kao I, Pruß A, Georgieva R, Bäumler H. Riboflavin: The Health Benefits of a Forgotten Natural Vitamin. Int J Mol Sci. 2020 Jan 31;21(3):950. doi: 10.3390/ijms21030950. PMID: 32023913; PMCID: PMC7037471.
Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine
prophylaxis. A randomized controlled trial. Neurology. 1998 Feb;50(2):466-70. doi:
1212/wnl.50.2.466. PMID: 9484373.
MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2008 Nov;23(11):1300-4. doi: 10.1177/0883073808318053. PMID: 18984840.
Penzien DB, Irby MB, Smitherman TA, Rains JC, Houle TT. Well-Established and Empirically Supported Behavioral Treatments for Migraine. Curr Pain Headache Rep. 2015 Jul;19(7):34. doi: 10.1007/s11916-015-0500-5. PMID: 26065542.
Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA, Vickers A, White AR. Acupuncture for the prevention of episodic migraine. Cochrane Database Syst
medication abuse]. Rev Neurol. 2013 Oct 16;57(8):347-53. Spanish. PMID: 24081889.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new mi-graine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1. PMID: 29691490.
Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opinion Ther Targets. 2020
Feb;24(2):91-100. doi: 10.1080/14728222.2020.1724285. Epub 2020 Feb 13. PMID:
; PMCID: PMC7050542.
Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019 Jul 16;9(7):e027953. doi: 10.1136/ bmjopen-2018-027953. PMID: 31315864; PMCID: PMC6661560.
Boczarska-Jedynak M, Sławek J. Practical aspects of treatment of chronic migraine with botulinum toxin type A. Pol. Overview Neurol 2017;13(4):189-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Tatiana Żymła, Dominika Pokładnik, Jakub Szczerba, Adam Podsiedlik, Alicja Poloczek, Agata Stefanowicz, Katarzyna Jeleń, Szymon Pokora, Paweł Sojka, Karolina Pokora
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 284
Number of citations: 0